Skip to main navigation Main navigation About Us Pipeline & Programs Clinical Trials Investors Careers Investors Corporate Profile Alpine is a clinical-stage specialty pharmaceutical company focused on discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune/inflammatory diseases. Our proprietary Variant Immunoglobulin Domain™ (“vIgD™”) scientific platform uses a process known as directed evolution to create therapeutics potentially capable of modulating human immune system proteins. Our vIgD platform creates molecules which can be formatted in many different ways, including standard Fc fusion proteins, localized Fc fusion proteins, and monoclonal antibody fusion proteins as well as formulated as a Transmembrane Immunomodulatory Protein (“TIP™”) or as a Secreted Immunomodulatory Protein (“SIP™”). News and Press Releases Summary Toggle Alpine Immune Sciences Announces Participation in Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference SEATTLE --(BUSINESS WIRE)--Nov. 22, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a fireside chat at Read More Summary Toggle Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2021 Financial Results - Recent private placement enables expansion and acceleration of development plans across the portfolio - - Plenary presentation for ALPN-303 at the American College of Rheumatology Convergence 2021 Annual Meeting highlighting best in class potential - SEATTLE --(BUSINESS WIRE)--Nov. Read More Summary Toggle Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting - ALPN-303 demonstrates superior immunomodulatory activity and efficacy in preclinical models - - Phase 1 study to begin Q4 2021 - SEATTLE --(BUSINESS WIRE)--Nov. 8, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company, today announced a presentation in Read More Stock Quote Change Volume 52 Week High 52 Week Low Nov 3, 2021 12:35 AM EDT Toolkit CONTACT 188 East Blaine Street Suite 200 Seattle, WA 98102 206-788-4545 SITEMAP About Us Pipelines & Programs Clinical Trials Investors Careers Contact Us Legal TWITTER @AlpineImmuneSci LATEST TWEETS Tweets by @AlpineImmuneSci © 2021 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.